Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of CLP 227.78 trillion. The enterprise value is 248.94 trillion.
| Market Cap | 227.78T |
| Enterprise Value | 248.94T |
Important Dates
The next estimated earnings date is Tuesday, February 3, 2026.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Dec 15, 2025 |
Share Statistics
| Current Share Class | 2.48B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.91% |
| Shares Change (QoQ) | -0.60% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 79.35% |
| Float | 2.48B |
Valuation Ratios
The trailing PE ratio is 12.44 and the forward PE ratio is 10.99.
| PE Ratio | 12.44 |
| Forward PE | 10.99 |
| PS Ratio | 3.69 |
| PB Ratio | 4.56 |
| P/TBV Ratio | 15.84 |
| P/FCF Ratio | 18.15 |
| P/OCF Ratio | 13.88 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.57, with an EV/FCF ratio of 19.84.
| EV / Earnings | 13.60 |
| EV / Sales | 4.25 |
| EV / EBITDA | 8.57 |
| EV / EBIT | 10.05 |
| EV / FCF | 19.84 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.80.
| Current Ratio | 1.66 |
| Quick Ratio | 1.09 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | 1.30 |
| Debt / FCF | 3.17 |
| Interest Coverage | 21.34 |
Financial Efficiency
Return on equity (ROE) is 39.49% and return on invested capital (ROIC) is 19.31%.
| Return on Equity (ROE) | 39.49% |
| Return on Assets (ROA) | 13.76% |
| Return on Invested Capital (ROIC) | 19.31% |
| Return on Capital Employed (ROCE) | 26.94% |
| Revenue Per Employee | 834.72M |
| Profits Per Employee | 247.34M |
| Employee Count | 75,000 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 2.24 |
Taxes
In the past 12 months, Merck & Co. has paid 2.67 trillion in taxes.
| Income Tax | 2.67T |
| Effective Tax Rate | 12.71% |
Stock Price Statistics
The stock price has decreased by -20.50% in the last 52 weeks. The beta is 0.39, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -20.50% |
| 50-Day Moving Average | 84.26 |
| 200-Day Moving Average | 87.40 |
| Relative Strength Index (RSI) | 99.98 |
| Average Volume (20 Days) | 5 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.34 |
Income Statement
In the last 12 months, Merck & Co. had revenue of CLP 61.77 trillion and earned 18.30 trillion in profits. Earnings per share was 7,265.86.
| Revenue | 61.77T |
| Gross Profit | 48.09T |
| Operating Income | 26.15T |
| Pretax Income | 20.98T |
| Net Income | 18.30T |
| EBITDA | 30.31T |
| EBIT | 26.15T |
| Earnings Per Share (EPS) | 7,265.86 |
Balance Sheet
The company has 17.51 trillion in cash and 39.79 trillion in debt, giving a net cash position of -22,270.89 billion.
| Cash & Cash Equivalents | 17.51T |
| Total Debt | 39.79T |
| Net Cash | -22,270.89B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 49.91T |
| Book Value Per Share | 20,045.23 |
| Working Capital | 18.20T |
Cash Flow
In the last 12 months, operating cash flow was 16.41 trillion and capital expenditures -3,861.83 billion, giving a free cash flow of 12.55 trillion.
| Operating Cash Flow | 16.41T |
| Capital Expenditures | -3,861.83B |
| Free Cash Flow | 12.55T |
| FCF Per Share | n/a |
Margins
Gross margin is 77.85%, with operating and profit margins of 42.33% and 29.63%.
| Gross Margin | 77.85% |
| Operating Margin | 42.33% |
| Pretax Margin | 33.96% |
| Profit Margin | 29.63% |
| EBITDA Margin | 49.07% |
| EBIT Margin | 42.33% |
| FCF Margin | 20.31% |
Dividends & Yields
This stock pays an annual dividend of 3,050.72, which amounts to a dividend yield of 2,979.22%.
| Dividend Per Share | 3,050.72 |
| Dividend Yield | 2,979.22% |
| Dividend Growth (YoY) | 2.90% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 41.99% |
| Buyback Yield | 0.91% |
| Shareholder Yield | 2,980.14% |
| Earnings Yield | 8.04% |
| FCF Yield | 5.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Merck & Co. has an Altman Z-Score of 3.89 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.89 |
| Piotroski F-Score | 5 |